Valuation: Addex Therapeutics Ltd

Market Cap 2.83M 3.42M 3.05M 2.57M 4.85M 325M 4.94M 34M 13.31M 169M 12.82M 12.55M 540M P/E 2024
0.8x
P/E 2025 -0.88x
Enterprise Value 1.22M 1.48M 1.32M 1.11M 2.1M 141M 2.14M 14.72M 5.76M 73.21M 5.55M 5.44M 234M EV / Sales 2024
5.67x
EV / Sales 2025 28.1x
Free-Float
43.94%
Yield 2024 *
-
Yield 2025 -
1 day+4.72%
1 week-2.63%
Current month+7.77%
1 month-9.02%
3 months-43.65%
6 months-52.77%
Current year-59.93%
1 week 0.02
Extreme 0.0208
0.02
1 month 0.02
Extreme 0.018
0.03
Current year 0.02
Extreme 0.018
0.07
1 year 0.02
Extreme 0.018
0.07
3 years 0.02
Extreme 0.018
0.26
5 years 0.02
Extreme 0.018
1.38
10 years 0.02
Extreme 0.018
4
Manager TitleAgeSince
Chief Executive Officer 58 2013-05-31
Director of Finance/CFO 40 2017-05-31
Chief Tech/Sci/R&D Officer 69 2016-11-27
Director TitleAgeSince
Director/Board Member 56 2018-05-31
Director/Board Member 58 2014-12-31
Chairman 77 -
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Issuer sale

Chief Technology Officer

-885,674 0.4051%
9/2/26 Issuer sale

Director

-539,122 0.2466%
9/2/26 Issuer sale

Chief Financial Officer

-1,205,816 0.5515%
Change 5-day change 1-year change 3-year change Capi.($)
+4.72%-2.63%-62.37%-66.77% 3.22M
+0.21%-7.67%+61.07%+71.32% 68.92B
+1.66%-9.54%+10.39%+60.04% 51.9B
+3.14%+4.61%+15.36%+44.42% 48.73B
+3.45%+5.01%+32.37%+35.96% 43.13B
-2.20%-5.78%+298.44%+532.76% 41.48B
+6.43%+2.76%+16.56%+109.23% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.74%-5.30%-12.09%-12.92% 22.27B
Average +1.82%-4.21%+41.27%+81.82% 37.3B
Weighted average by Cap. +1.58%-3.49%+56.57%+105.30%

Financials

2024 2025
Net sales 410K 495K 442K 373K 703K 47.1M 716K 4.93M 1.93M 24.51M 1.86M 1.82M 78.33M 173K 209K 186K 157K 296K 19.86M 302K 2.08M 813K 10.33M 784K 767K 33.02M
Net income 7.06M 8.52M 7.6M 6.42M 12.09M 811M 12.32M 84.81M 33.19M 422M 31.99M 31.32M 1.35B -6.73M -8.13M -7.25M -6.12M -11.53M -773M -11.75M -80.87M -31.65M -402M -30.51M -29.86M -1.29B
Net Debt -3.3M -3.99M -3.55M -3M -5.66M -379M -5.76M -39.66M -15.52M -197M -14.96M -14.65M -630M -1.6M -1.94M -1.73M -1.46M -2.75M -184M -2.8M -19.28M -7.55M -95.88M -7.27M -7.12M -306M
Projected Income Statement - Annual - Addex Therapeutics Ltd
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Employees
3
Date Price Change Volume
26-10-15 CHF 0.0222 +4.72% 1,062,587
26-10-14 CHF 0.0212 -9.40% 173,670
26-10-13 CHF 0.0234 0.00% 378,303
26-10-12 CHF 0.0234 +0.86% 203,713
26-10-09 CHF 0.0232 -2.52% 336,028
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Addex Therapeutics Ltd

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Addex Therapeutics Ltd
  1. Stock Market
  2. Stocks
  3. ADXN Stock